ARTICLE | Clinical News
Omadacycline: Phase III data
June 20, 2016 7:00 AM UTC
Top-line data from the modified intent-to-treat (mITT) population of the double-blind, international Phase III OASIS trial in 645 patients with ABSSSIs showed that once-daily IV-to-oral omadacycline ...